Algert Global LLC Arcellx, Inc. Transaction History

Algert Global LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$49.74 - $66.98 $343,255 - $462,228	6,901 Added 24.38%	35,211 $1.94 Million
Q1 2024 May 14, 2024	BUY	$51.85 - $73.49 $991,372 - $1.41 Million	19,120 Added 208.05%	28,310 $1.97 Million
Q4 2023 Feb 14, 2024	SELL	$31.75 - $57.99 $17,780 - $32,474	-560 Reduced 5.74%	9,190 $510,000
Q2 2023 Aug 14, 2023	SELL	$27.49 - $46.9 $271,381 - $462,996	-9,872 Reduced 50.31%	9,750 $308,000
Q1 2023 May 12, 2023	BUY	$26.92 - $33.94 $323,632 - $408,026	12,022 Added 158.18%	19,622 $605,000
Q4 2022 Feb 13, 2023	BUY	$17.18 - $33.0 $130,568 - $250,800	7,600 New	7,600 $235,000

204

44.2M

2.23M

907K

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $3.31B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.